China Biologic Reports Receipt Of Competing Non-Binding Purchase Proposal From Consortium Consisting Of Feng Tai, GL Sandrose, Etc., At $118/Share In Cash, Up From Prior Offer From CCRE Holdings At $110/Share In Cash
luke@benzinga.com